HER2-Low Breast Cancer: Molecular Characteristics and Prognosis

Intrinsic molecular subtypes of HER2+ breast cancer

HER2-positive (HER2+) breast cancer is a clinically and biologically heterogeneous disease. According to gene expression profiling, 4 main intrinsic molecular subtypes of breast cancer (Luminal A, Luminal B, HER2-enriched [HER2-E], Basal-like) can be identified, although HER2-E predominates (~50-60%). From a molecular perspective, HER2-E tumors are characterized by high expression of ERBB2 and ...

Development of RNA aptamers as molecular probes for HER2+ breast cancer study using cell-SELEX

Objective(s): Development of molecules that specifically recognize cancer cells is one of the major areas in cancer research. Human epidermal growth factor receptor 2 (HER2) is specifically expressed on the surface of breast cancer cells. HER2 is associated with an aggressive phenotype and poor prognosis. In this study we aimed to isolate RNA aptamers that specifically bind to HER2 overexpressi...

Cytoplasmic Her2/neu immunohistochemical staining in breast cancer; From a molecular point of view

HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients

PURPOSE The efficacy of trastuzumab in Chinese breast cancer (BC) patients has rarely been reported. This study was designed to compare the clinical outcomes of HER2-positive BC patients receiving or not receiving trastuzumab treatment and HER2-negative BC patients. PATIENTS AND METHODS This study involved three groups of patients. The first group was 115 human epidermal growth factor recepto...

HER2 and Breast Cancer Outcome

Background: Breast cancer is the most common cancer in females in the UK and has greater severity in patients who overexpress human epidermal growth receptor 2 (HER2) proteins in the breast tissue. Trastuzumab is a humanised monoclonal antibody and is targeted towards blocking the HER2 pathway and effectively reduces the recurrence of breast cancer and associated mortality. However, trastuzumab...